ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $28.00K; Additional Paid in CapitalUSD $737.12M; Retained Earnings (Accumulated Deficit)USD $-565.34M; Stockholders' Equity Attributable to ParentUSD $171.81M.
- 2026-03-31: Common Stock, Value, IssuedUSD $28.00K; Additional Paid in CapitalUSD $732.89M; Retained Earnings (Accumulated Deficit)USD $-541.55M; Stockholders' Equity Attributable to ParentUSD $191.36M.
- 2025-12-31: Common Stock, Value, IssuedUSD $28.00K; Additional Paid in CapitalUSD $728.55M; Retained Earnings (Accumulated Deficit)USD $-514.59M; Stockholders' Equity Attributable to ParentUSD $213.99M.
- 2025-09-30: Common Stock, Value, IssuedUSD $27.00K; Additional Paid in CapitalUSD $710.04M; Retained Earnings (Accumulated Deficit)USD $-485.51M; Stockholders' Equity Attributable to ParentUSD $224.56M.
ARCTURUS THERAPEUTICS HOLDINGS INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Treasury Stock, Common, Shares shares |
|---|---|---|---|---|---|---|
| 2026-06-30 | $28.00K | $737.12M | $-565.34M | $171.81M | 3 month · $4.23M | (m) |
| 2026-03-31 | $28.00K | $732.89M | $-541.55M | $191.36M | 3 month · $4.33M | (m) |
| 2025-12-31 | $28.00K | $728.55M | $-514.59M | $213.99M | 12 month · $25.41M | (m) |
| 2025-09-30 | $27.00K | $710.04M | $-485.51M | $224.56M | 3 month · $5.73M | (m) |
| 2025-06-30 | $27.00K | $703.09M | $-472.06M | $231.05M | 3 month · $6.20M | (m) |
| 2025-03-31 | $27.00K | $696.62M | $-462.88M | $233.76M | 3 month · $6.66M | (m) |
| 2024-12-31 | $27.00K | $689.76M | $-448.81M | $240.98M | 12 month · $37.99M | (m) |
| 2024-09-30 | $27.00K | $680.64M | $-418.80M | $261.87M | 3 month · $9.49M | (m) |
| 2024-06-30 | $27.00K | $670.46M | $-411.90M | $258.58M | 3 month · $9.42M | (m) |
| 2024-03-31 | $27.00K | $658.63M | $-394.68M | $263.97M | 3 month · $10.09M | (m) |
| 2023-12-31 | $27.00K | $646.35M | $-367.87M | $278.51M | 12 month · $34.65M | (m) |
| 2023-09-30 | $27.00K | $636.19M | $-356.16M | $280.06M | 3 month · $9.27M | (m) |
| 2023-06-30 | $27.00K | $625.09M | $-339.94M | $285.18M | 3 month · $8.38M | (m) |
| 2023-03-31 | $27.00K | $616.61M | $-287.39M | $329.25M | 3 month · $8.18M | (m) |
| 2022-12-31 | $27.00K | $608.43M | $-338.14M | $270.31M | 12 month · $30.61M | (m) |
| 2022-09-30 | $26.00K | $601.13M | $-455.49M | $145.67M | 3 month · $9.44M | (m) |
| 2022-06-30 | $26.00K | $590.91M | $-420.22M | $170.72M | 3 month · $7.27M 6 month · $14.64M | (m) |
| 2022-03-31 | $26.00K | $583.38M | $-398.66M | $184.75M | 3 month · $7.37M | (m) |
| 2021-12-31 | $26.00K | $575.67M | $-347.49M | $228.21M | 12 month · $28.91M | (m) |
| 2021-09-30 | $26.00K | $567.93M | $-308.83M | $259.13M | 3 month · $6.87M 9 month · $21.40M | (m) |
| 2021-06-30 | $26.00K | $560.37M | $-254.74M | $305.65M | 3 month · $7.54M 6 month · $14.53M | (m) |
| 2021-03-31 | $26.00K | $552.74M | $-200.16M | $352.61M | 3 month · $6.99M | (m) |
| 2020-12-31 | $26.00K | $540.34M | $-143.82M | $396.55M | 12 month · $6.76M | (m) |
| 2020-09-30 | $25.00K | $374.32M | $-112.71M | $261.63M | 3 month · $1.99M 9 month · $3.94M | (m) |
| 2020-06-30 | $21.00K | $185.11M | $-91.71M | $93.42M | 3 month · $1.10M 6 month · $1.95M | (m) |
| 2020-03-31 | $15.00K | $98.41M | $-81.44M | $16.98M | 3 month · $849.00K | (m) |
| 2019-12-31 | $15.00K | $97.44M | $-71.67M | $25.79M | 12 month · $1.98M | (m) |
| 2019-09-30 | $15.00K | $96.56M | $-60.68M | $35.90M | 3 month · $383.00K 9 month · $1.19M | (m) |
| 2019-06-30 | $13.00K | $74.85M | $-53.25M | $21.62M | 3 month · $403.00K 6 month · $802.00K | (m) |
| 2019-03-31 | (m) | (m) | (m) | $6.35M | 3 month · $399.00K | (m) |
| 2018-12-31 | $214.00K | $58.30M | $-44.87M | $13.64M | 12 month · $1.26M | 43.00K |
| 2018-09-30 | (m) | (m) | (m) | $14.15M | 3 month · $587.00K 9 month · $753.00K | (m) |
| 2018-06-30 | (m) | (m) | (m) | $17.80M | 3 month · $140.00K 6 month · $166.00K | (m) |
| 2018-03-31 | (m) | (m) | (m) | $27.55M | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | $33.79M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |